Exorex (Linotar) Psoriasis Medication
  International Distributor
Call Toll Free (US and Canada)
US / Canada: 1-888-604-4561
International: +372-82138479
Email: helpdesk@exorex.com

Exorex (Linotar) Psoriasis Medication

Exorex Gel 1 &2 (Exorex Lotion 1%) : Product Profile

Exorex (also known as Linotar® in some countries in the Southern Hemisphere) is a highly
innovative topical dermatological preparation indicated for the treatment of Psoriasis and Eczema. The active ingredient is prepared coal tar. In addition, Exorex Gel 1 & 2 feature a sophisticated vehicle consisting of a specific combination of free essential fatty acids. Exorex®, as a result, has been successfully applied without most of the burdens that are usually associated with the use of more conventional, coal tar preparations.

Contrary to most traditional coal tar preparations, Exorex Gel 1 & 2 produce an extremely
rapid and almost complete penetration (1). The excipients have a transdermal carrier function,
bringing coal tar much more efficiently through the affected skin. Thanks to this special
feature and due to the general physical properties of Exorex PSE Stabilizing Cream, the product
does not provoke as much of the yellow staining that is common to coal tar products, nor does
it produce the traditional strong coal tar smell: The product "disappears" within minutes.

Exorex has been developed by Meyer Zall Laboratories of South Africa and was first launched in 1993 in its home market, South Africa, for both the indications Psoriasis and Eczema, as part of a complete treatment method.Since 1993, Exorex has been successfully introduced in Australia, New Zealand, and in a number of African and Asian countries, as well as in the U.S.A., Canada, Israel,and in the United Kingdom. In 1996 Exorex was registered in Austria, the Netherlands and Luxembourg

Exorex has been shown to be clinically and statistically equally effective as the vitamin D derivate calcipotriol (also known as Daivonex®, Dovonex® or Psorcutan® Creme) and superior to any coal tar in the treatment of psoriasis, through objective parameters and in patient preference scores. Results of a recently completed Austrian (University of Vienna, 2001) 40-patient clinical trial proves this point (2). These results closely match those of an earlier 18-patient US pilot study in which Exorex is compared with the vitamin D derivate Dovonex (calcipotriene) (3).

(1) For further information on the trans dermal carrier, go to: